Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

InflaRx N.V. (IFRX)

2.5   -0.09 (-3.47%) 12-05 16:00
Open: 2.56 Pre. Close: 2.59
High: 2.5848 Low: 2.48
Volume: 34,194 Market Cap: 111(M)

Technical analysis

as of: 2022-12-06 9:19:33 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.99     One year: 3.23
Support: Support1: 2.24    Support2: 1.86
Resistance: Resistance1: 2.56    Resistance2: 2.76
Pivot: 2.51
Moving Average: MA(5): 2.59     MA(20): 2.55
MA(100): 2.45     MA(250): 2.44
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 67.6     %D(3): 71.1
RSI: RSI(14): 48
52-week: High: 4.98  Low: 0.77
Average Vol(K): 3-Month: 86 (K)  10-Days: 57 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IFRX ] has closed above bottom band by 45.3%. Bollinger Bands are 57.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.59 - 2.6 2.6 - 2.61
Low: 2.45 - 2.46 2.46 - 2.48
Close: 2.47 - 2.5 2.5 - 2.52

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Headline News

Wed, 30 Nov 2022
Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth? - Simply Wall St

Sat, 19 Nov 2022
Raymond James Has 5 ‘Strong Buy’ Stocks Under $10 With 85% to 370% Upside Potential - 24/7 Wall St.

Sat, 12 Nov 2022
SVB Leerink Reiterates "Outperform" Rating for InflaRx (NASDAQ:IFRX) - MarketBeat

Wed, 09 Nov 2022
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 - Marketscreener.com

Wed, 09 Nov 2022
InflaRx GAAP EPS of -$0.18 (NASDAQ:IFRX) - Seeking Alpha

Fri, 09 Sep 2022
InflaRx to Present at Upcoming Scientific and Investor Conferences - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 44 (M)
Shares Float 38 (M)
% Held by Insiders 14.8 (%)
% Held by Institutions 9.4 (%)
Shares Short 409 (K)
Shares Short P.Month 429 (K)

Stock Financials

EPS -1.28
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.25
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.1
Return on Equity (ttm) -31.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.22
Qtrly Earnings Growth 0
Operating Cash Flow -40 (M)
Levered Free Cash Flow -108 (M)

Stock Valuations

PE Ratio -1.97
PEG Ratio 0
Price to Book value 1.11
Price to Sales 0
Price to Cash Flow -2.75

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.